VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide invivo

Sixiang Shi; Kai Yang; Hao Hong; Feng Chen; Hector F. Valdovinos; Shreya Goel; Todd E. Barnhart; Zhuang Liu; Weibo Cai

doi:10.1016/j.biomaterials.2014.10.061

VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide invivo

Sixiang Shi, Kai Yang, Hao Hong, Feng Chen, Hector F. Valdovinos, Shreya Goel, Todd E. Barnhart, Zhuang Liu, Weibo Cai

Research output: Journal article publication › Journal article › Academic research › peer-review

68 Citations (Scopus)

Abstract

Although graphene oxide (GO) has recently been considered as a highly attractive nanomaterial for future cancer imaging and therapy, it is still a major challenge to improve its invivo tumor active targeting efficiency. Here in this full article, we demonstrated the successful and significantly enhanced invivo tumor vasculature targeting efficacy of well-functionalized GO nanoconjugates by using vascular endothelial growth factor 121 (VEGF121) as the targeting ligand. As-developed GO nanoconjugate exhibits excellent invivo stability, specific invitro and invivo vascular endothelial growth factor receptor (VEGFR) targeting, significantly enhanced tumor accumulation (>8 %ID/g) as well as high tumor-to-muscle contrast, showing great potential for future tumor targeted imaging and therapy.

Original language	English
Pages (from-to)	39-46
Number of pages	8
Journal	Biomaterials
Volume	39
DOIs	https://doi.org/10.1016/j.biomaterials.2014.10.061
Publication status	Published - Jan 2015
Externally published	Yes

Keywords

Graphene oxide (GO)
Positron emission tomography (PET)
Vasculature targeting
VEGF

ASJC Scopus subject areas

Bioengineering
Ceramics and Composites
Biophysics
Biomaterials
Mechanics of Materials

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

More information

10.1016/j.biomaterials.2014.10.061

Cite this

@article{80fa85a49a2047d59b11fda0c24dd4fb,

title = "VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide invivo",

abstract = "Although graphene oxide (GO) has recently been considered as a highly attractive nanomaterial for future cancer imaging and therapy, it is still a major challenge to improve its invivo tumor active targeting efficiency. Here in this full article, we demonstrated the successful and significantly enhanced invivo tumor vasculature targeting efficacy of well-functionalized GO nanoconjugates by using vascular endothelial growth factor 121 (VEGF121) as the targeting ligand. As-developed GO nanoconjugate exhibits excellent invivo stability, specific invitro and invivo vascular endothelial growth factor receptor (VEGFR) targeting, significantly enhanced tumor accumulation (>8 %ID/g) as well as high tumor-to-muscle contrast, showing great potential for future tumor targeted imaging and therapy.",

keywords = "Graphene oxide (GO), Positron emission tomography (PET), Vasculature targeting, VEGF",

author = "Sixiang Shi and Kai Yang and Hao Hong and Feng Chen and Valdovinos, {Hector F.} and Shreya Goel and Barnhart, {Todd E.} and Zhuang Liu and Weibo Cai",

note = "Funding Information: This work is supported, in part, by the University of Wisconsin–Madison , the National Institutes of Health (NIBIB/NCI 1R01CA169365 and P30CA014520 ), the Department of Defense ( W81XWH-11-1-0644 ), the American Cancer Society ( 125246-RSG-13-099-01-CCE ), the National Basic Research Program of China (973 Program, 2012CB932601 & 2011CB911002 ), and the National Natural Science Foundation of China ( 51002100 & 51222203 ). Publisher Copyright: {\textcopyright} 2014 Elsevier Ltd. Copyright: Copyright 2015 Elsevier B.V., All rights reserved.",

year = "2015",

month = jan,

doi = "10.1016/j.biomaterials.2014.10.061",

language = "English",

volume = "39",

pages = "39--46",

journal = "Biomaterials",

issn = "0142-9612",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide invivo

AU - Shi, Sixiang

AU - Yang, Kai

AU - Hong, Hao

AU - Chen, Feng

AU - Valdovinos, Hector F.

AU - Goel, Shreya

AU - Barnhart, Todd E.

AU - Liu, Zhuang

AU - Cai, Weibo

N1 - Funding Information: This work is supported, in part, by the University of Wisconsin–Madison , the National Institutes of Health (NIBIB/NCI 1R01CA169365 and P30CA014520 ), the Department of Defense ( W81XWH-11-1-0644 ), the American Cancer Society ( 125246-RSG-13-099-01-CCE ), the National Basic Research Program of China (973 Program, 2012CB932601 & 2011CB911002 ), and the National Natural Science Foundation of China ( 51002100 & 51222203 ). Publisher Copyright: © 2014 Elsevier Ltd. Copyright: Copyright 2015 Elsevier B.V., All rights reserved.

PY - 2015/1

Y1 - 2015/1

N2 - Although graphene oxide (GO) has recently been considered as a highly attractive nanomaterial for future cancer imaging and therapy, it is still a major challenge to improve its invivo tumor active targeting efficiency. Here in this full article, we demonstrated the successful and significantly enhanced invivo tumor vasculature targeting efficacy of well-functionalized GO nanoconjugates by using vascular endothelial growth factor 121 (VEGF121) as the targeting ligand. As-developed GO nanoconjugate exhibits excellent invivo stability, specific invitro and invivo vascular endothelial growth factor receptor (VEGFR) targeting, significantly enhanced tumor accumulation (>8 %ID/g) as well as high tumor-to-muscle contrast, showing great potential for future tumor targeted imaging and therapy.

AB - Although graphene oxide (GO) has recently been considered as a highly attractive nanomaterial for future cancer imaging and therapy, it is still a major challenge to improve its invivo tumor active targeting efficiency. Here in this full article, we demonstrated the successful and significantly enhanced invivo tumor vasculature targeting efficacy of well-functionalized GO nanoconjugates by using vascular endothelial growth factor 121 (VEGF121) as the targeting ligand. As-developed GO nanoconjugate exhibits excellent invivo stability, specific invitro and invivo vascular endothelial growth factor receptor (VEGFR) targeting, significantly enhanced tumor accumulation (>8 %ID/g) as well as high tumor-to-muscle contrast, showing great potential for future tumor targeted imaging and therapy.

KW - Graphene oxide (GO)

KW - Positron emission tomography (PET)

KW - Vasculature targeting

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84919468821&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2014.10.061

DO - 10.1016/j.biomaterials.2014.10.061

M3 - Journal article

C2 - 25477170

AN - SCOPUS:84919468821

SN - 0142-9612

VL - 39

SP - 39

EP - 46

JO - Biomaterials

JF - Biomaterials

ER -

VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide invivo

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

More information

Other files and links

Fingerprint

Cite this